Key result
Review summarizes HCM genetics, pathophysiology, and management focusing on transcoronary alcohol septal ablation.
Why the study?
Hypertrophic Cardiomyopathy presents with variable morphologic and hemodynamic abnormalities and clinical manifestations, requiring effective management strategies including non-surgical septal reduction.
Answers are grounded in this paper and cite their sources.
This review summarizes the genetics, pathophysiology, and management of hypertrophic cardiomyopathy, focusing on transcoronary alcohol septal ablation.
A b s t r A c t Hypertrophic Cardiomyopathy (HCM) is a genetic disease caused by a variety of mutations in proteins, mostly but not exclusively, of the cardiac sarcomere. It is characterized by hypertrophy of the left ventricle (LV), often with obstruction of the LV outflow tract (LVOT), in the absence of another cause, such as hypertension or aortic stenosis, capable of producing the degree of hypertrophy observed. It presents with markedly variable morphologic and hemodynamic abnormalities and clinical manifestations. The present review will briefly summarize the genetics, pathophysiology, clinical features and management of this disease and will mainly deal with the non-surgical reduction of septal hypertrophy by means of transcoronary alcohol septal ablation.
No takes yet. Share an insight, caveat, or question.
Tsilakis et al. (2008) conducted a review in Hypertrophic Cardiomyopathy. Transcoronary alcohol septal ablation was evaluated. This review summarizes the genetics, pathophysiology, clinical features, and management of hypertrophic cardiomyopathy, focusing on transcoronary alcohol septal ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: